Federal President Steinmeier visits LTS Lohmann Therapie-Systeme AG in Andernach
Andernach, 10/16/2025– LTS LOHMANN Therapie-Systeme AG (“LTS”), a global leader in the development and manufacturing of innovative drug delivery systems, had the great honor today of welcoming Federal President of Germany, Frank-Walter Steinmeier, to its Andernach headquarter as part of his “Ortszeit Deutschland” tour. The focus of the visit was the presentation of LTS’s innovative microneedle technology, which is opening up new pathways in drug delivery.
Dr. Claudia Schaefer, Chief Operating Officer of LTS, commented:
“It is a great pleasure for us to present our company and our innovations to the Federal President as part of the ‘Ortszeit Deutschland’ initiative. LTS stands for pioneering drug delivery systems that benefit patients worldwide. We are particularly pleased to showcase our microneedle technology, which provides new opportunities in drug delivery and is being developed at our Andernach site.”
Dr. Detlev Radloff, President LTS EMEA/A, added:
“The visit of the Federal President is a special recognition of the commitment and innovative strength of our entire team. Our investments in research, development, and production at the Andernach site not only secure jobs but also strengthen the competitiveness of Germany as a pharmaceutical location.”
During the visit, LTS presented the development from transdermal patches to the latest microneedle patches, which offer a painless, safe, and sustainable alternative to traditional injections. The microneedle technology enables the administration of active ingredients and vaccines through the skin—simple, painless, and potentially suitable for self-administration.
In addition to the technology presentation, the Federal President also gained insights into apprenticship at LTS and the current investments in the Andernach site.
About LTS Lohmann Therapie-Systeme AG
We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.
For further information, please contact:
Dr Iris Schnitzler: iris.schnitzler@ltslohmann.com
